Coronary heart disease events in the Women’s Health Initiative hormone trials: effect modification by metabolic syndrome A nested case-control study within the Women’s Health Initiative randomized clinical trials
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Our objective was to determine whether metabolic syndrome (MetS) or its components modified the effect of hormone therapy (HT) on the risk of coronary heart disease (CHD) events in the Women's Health Initiative clinical trials. METHODS: We performed a nested case-control study of incident CHD events during the first 4 years of follow-up in the Women's Health Initiative HT trials (estrogen plus progestin therapy [EPT] and estrogen therapy [ET]). There were 359 incident cases of CHD during follow-up. After the exclusion of women with cardiovascular disease (n = 90), diabetes, or hypertension at baseline (n = 103), 166 CHD cases were matched to 524 controls on age, randomization date, and hysterectomy status. MetS classification required at least three of five Adult Treatment Panel III criteria. Analyses by χ and t tests for heterogeneity and logistic regression were performed. Postmenopausal women (n = 27,347) aged 50 to 79 years from 40 US clinical centers participated. Daily conjugated equine estrogens (0.625 mg) and medroxyprogesterone acetate (2.5 mg; EPT) or conjugated equine estrogens (0.625 mg; ET) were compared with placebo. The main outcome measure was the odds for CHD with HT use versus placebo by MetS status. RESULTS: MetS modified the risk of CHD events with HT. In the pooled analysis, risk was increased with HT versus placebo in women with MetS (odds ratio, 2.26; 95% CI, 1.26-4.07), whereas women without MetS were not found to have an increased risk for a CHD event with HT (odds ratio, 0.97; 95% CI, 0.58-1.61; P for interaction = 0.03). Results of the EPT and ET trials, when examined separately, were similar. The constellation of MetS variables was more predictive of risk from HT than MetS components assessed individually. When women with diabetes or hypertension were included in the analysis, statistically significant effect modification was not detected. CONCLUSIONS: MetS at baseline in women without prior cardiovascular disease, diabetes, or hypertension at baseline identifies women who are more likely to have had adverse coronary outcomes on HT. CHD risk stratification is recommended before initiating HT. The basis for the greater risk of CHD events with HT among women with MetS requires further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause
Rossouw, J. E., Prentice, R. L., Manson, J. E., Wu, L., Barad, D., Barnabei, V. M., Ko, M., LaCroix, A. Z., Margolis, K. L., & Stefanick, M. L. (2007) · JAMA · doi:10.1001/jama.297.13.1465 · Cited by 1,741 · cited 1×
“1 years, respectively.(1,2) All centrally adjudicated cases of CHD (nonfatal myocardial infarction [MI] or fatal CHD) occurring during the first 4 years of follow-up are included in our nested case-control study within both RCT cohorts.”
BackgroundSelf-citationfor the Women’s Health Initiative Investigators, Margolis, K. L., Bonds, D. E., Rodabough, R. J., Tinker, L., Phillips, L. S., Allen, C., Bassford, T., Burke, G., Torrens, J., et al. (2004) · Diabetologia · doi:10.1007/s00125-004-1448-x · Cited by 599 · cited 1×
“01).(8) It is possible that the HTrelated reduction in diabetes incidence affected our ability to determine if effect modification occurred with HT.”
BackgroundSelf-citation
Cited by
Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline
Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2236 · Cited by 884
“In a nested case-control study in the WHI, women with MetS at baseline were twice as likely to have CHD events while taking oral MHT as with placebo (147).”
BackgroundIs there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?
Rozenberg, S., Al-Daghri, N., Aubertin-Leheudre, M., Brandi, M.-L., Cano, A., Collins, P., Cooper, C., Genazzani, A. R., Hillard, T., Kanis, J. A., et al. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05497-8 · Cited by 149
Effect of menopausal hormone therapy on components of the metabolic syndrome
Lovre, D., Lindsey, S. H., & Mauvais-Jarvis, F. (2017) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944716649358 · Cited by 44
Metadata
- Authors
- Wild, R. A., Wu, C., Curb, J. D., Martin, L. W., Phillips, L., Stefanick, M., Trevisan, M., & Manson, J. E.
- Venue
- Menopause
- Published
- 2013-03
- Volume
- 20
- Issue
- 3
- Pages
- 254-260
- ISSN
- 1072-3714 (ISSN-L)
- OpenAlex
- W1584027934
- Cited by
- 72
- References
- 3
- FWCI
- 5.98
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Coronary heart disease events in the Women’s Health Initiative hormone trials: effect modification by metabolic syndrome A nested case-control study within the Women’s Health Initiative randomized clinical trials. https://app.cochat.ai/papers/10.1097/gme.0b013e31826f80e0
- The paper
- Wild, R. A., Wu, C., Curb, J. D., Martin, L. W., Phillips, L., Stefanick, M., Trevisan, M., & Manson, J. E. (2013). Coronary heart disease events in the Women’s Health Initiative hormone trials: effect modification by metabolic syndrome A nested case-control study within the Women’s Health Initiative randomized clinical trials. Menopause. https://doi.org/10.1097/gme.0b013e31826f80e0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.